• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Whatsapp

+1 (877) 703-6664

Free to Use
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Tag: clinical trials

New Drugs

What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)

Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.

New Drugs

Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data

Learn what ensifentrine is, how its dual PDE3/4 inhibition works, and why it’s an emerging inhaled treatment option for COPD. Review its bronchodilatory and anti-inflammatory effects, phase 2b and phase 3 clinical trial results, and impact on lung function, symptoms, and exacerbations.

New Drugs

Deucravacitinib (TYK2 Inhibitor): Mechanism of Action, Clinical Trials & Psoriasis Benefits

Learn what deucravacitinib is, how this first-in-class selective TYK2 inhibitor works, and why it’s changing the treatment landscape for moderate-to-severe plaque psoriasis and other autoimmune diseases, with data from pivotal phase 3 clinical trials.

Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025
  • Home
  • Workspace
  • Contacts

Copyright © 2026 ConDrug All Rights Reserved.

Linkedin-in Handshake